Cargando…
Recent advances in genetic modification of adenovirus vectors for cancer treatment
Adenoviruses are widely used to deliver genes to a variety of cell types and have been used in a number of clinical trials for gene therapy and oncolytic virotherapy. However, several concerns must be addressed for the clinical use of adenovirus vectors. Selective delivery of a therapeutic gene by a...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5448613/ https://www.ncbi.nlm.nih.gov/pubmed/28266780 http://dx.doi.org/10.1111/cas.13228 |
_version_ | 1783239587101933568 |
---|---|
author | Yamamoto, Yuki Nagasato, Masaki Yoshida, Teruhiko Aoki, Kazunori |
author_facet | Yamamoto, Yuki Nagasato, Masaki Yoshida, Teruhiko Aoki, Kazunori |
author_sort | Yamamoto, Yuki |
collection | PubMed |
description | Adenoviruses are widely used to deliver genes to a variety of cell types and have been used in a number of clinical trials for gene therapy and oncolytic virotherapy. However, several concerns must be addressed for the clinical use of adenovirus vectors. Selective delivery of a therapeutic gene by adenovirus vectors to target cancer is precluded by the widespread distribution of the primary cellular receptors. The systemic administration of adenoviruses results in hepatic tropism independent of the primary receptors. Adenoviruses induce strong innate and acquired immunity in vivo. Furthermore, several modifications to these vectors are necessary to enhance their oncolytic activity and ensure patient safety. As such, the adenovirus genome has been engineered to overcome these problems. The first part of the present review outlines recent progress in the genetic modification of adenovirus vectors for cancer treatment. In addition, several groups have recently developed cancer‐targeting adenovirus vectors by using libraries that display random peptides on a fiber knob. Pancreatic cancer‐targeting sequences have been isolated, and these oncolytic vectors have been shown by our group to be associated with a higher gene transduction efficiency and more potent oncolytic activity in cell lines, murine models, and surgical specimens of pancreatic cancer. In the second part of this review, we explain that combining cancer‐targeting strategies can be a promising approach to increase the clinical usefulness of oncolytic adenovirus vectors. |
format | Online Article Text |
id | pubmed-5448613 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-54486132017-06-01 Recent advances in genetic modification of adenovirus vectors for cancer treatment Yamamoto, Yuki Nagasato, Masaki Yoshida, Teruhiko Aoki, Kazunori Cancer Sci Review Articles Adenoviruses are widely used to deliver genes to a variety of cell types and have been used in a number of clinical trials for gene therapy and oncolytic virotherapy. However, several concerns must be addressed for the clinical use of adenovirus vectors. Selective delivery of a therapeutic gene by adenovirus vectors to target cancer is precluded by the widespread distribution of the primary cellular receptors. The systemic administration of adenoviruses results in hepatic tropism independent of the primary receptors. Adenoviruses induce strong innate and acquired immunity in vivo. Furthermore, several modifications to these vectors are necessary to enhance their oncolytic activity and ensure patient safety. As such, the adenovirus genome has been engineered to overcome these problems. The first part of the present review outlines recent progress in the genetic modification of adenovirus vectors for cancer treatment. In addition, several groups have recently developed cancer‐targeting adenovirus vectors by using libraries that display random peptides on a fiber knob. Pancreatic cancer‐targeting sequences have been isolated, and these oncolytic vectors have been shown by our group to be associated with a higher gene transduction efficiency and more potent oncolytic activity in cell lines, murine models, and surgical specimens of pancreatic cancer. In the second part of this review, we explain that combining cancer‐targeting strategies can be a promising approach to increase the clinical usefulness of oncolytic adenovirus vectors. John Wiley and Sons Inc. 2017-05-07 2017-05 /pmc/articles/PMC5448613/ /pubmed/28266780 http://dx.doi.org/10.1111/cas.13228 Text en © 2017 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial (http://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Review Articles Yamamoto, Yuki Nagasato, Masaki Yoshida, Teruhiko Aoki, Kazunori Recent advances in genetic modification of adenovirus vectors for cancer treatment |
title | Recent advances in genetic modification of adenovirus vectors for cancer treatment |
title_full | Recent advances in genetic modification of adenovirus vectors for cancer treatment |
title_fullStr | Recent advances in genetic modification of adenovirus vectors for cancer treatment |
title_full_unstemmed | Recent advances in genetic modification of adenovirus vectors for cancer treatment |
title_short | Recent advances in genetic modification of adenovirus vectors for cancer treatment |
title_sort | recent advances in genetic modification of adenovirus vectors for cancer treatment |
topic | Review Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5448613/ https://www.ncbi.nlm.nih.gov/pubmed/28266780 http://dx.doi.org/10.1111/cas.13228 |
work_keys_str_mv | AT yamamotoyuki recentadvancesingeneticmodificationofadenovirusvectorsforcancertreatment AT nagasatomasaki recentadvancesingeneticmodificationofadenovirusvectorsforcancertreatment AT yoshidateruhiko recentadvancesingeneticmodificationofadenovirusvectorsforcancertreatment AT aokikazunori recentadvancesingeneticmodificationofadenovirusvectorsforcancertreatment |